Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
This paper presents a meta-modelling study of the response of positron emission tomography (PET) to radiolysis (radiolysis) and its applications to nuclear medicine and Radiology.
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding
The authors focus on the specification of appropriate volumes of interest (VoI) using PET in association with computed tomography (CT) to quantitate accurately the activity and volume of lesions and organs with positron emissiontomography (PET).
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
The finding that modifications in CAR design as well as T-cell dosing allowed for the complete eradication of systemic disease affects the design of clinical trials using this treatment strategy.
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
FDG uptake is lower in indolent than in aggressive lymphoma, and patients with NHL and SUV > 10 have a high likelihood for aggressive disease.
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Baseline CTC number was strongly associated with survival, without a threshold effect, which increased further when baseline prostate-specific antigen and albumin were included, and was predictive of survival, with no threshold effect.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed and its potential as a surrogate of clinical benefit is addressed.
Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.
- H. Yeung, R. Grewal, M. Gonen, H. Schöder, S. Larson
- MedicineJournal of nuclear medicine : official…
- 1 November 2003
Increased (18)F-FDG uptake is sometimes seen in individual muscles and in adipose tissue in the neck and shoulder region, axillae, mediastinum, and perinephric regions, and it is important to recognize this uptake pattern to avoid false interpretation of this benign normal variant as a malignant finding on (18).
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease.